By Fineline Cube 
Resight Therapeutics, a China‑based cell‑therapy pioneer founded in September 2024, announced the close of an Angel‑stage financing round led by Hofon Capital with co‑investment from the Hangzhou Science and Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund). The round raised tens of millions of RMB and will fund the company’s lead iPSC‑derived corneal endothelial cell (CEC) therapy as well as early‑stage projects powered by its proprietary AI‑augmented reprogramming platforms.
Financing Overview
| Item | Detail |
|---|---|
| Round Type | Angel round |
| Lead Investor | Hofon Capital |
| Co‑Investors | Hangzhou Science & Technology Innovation Group (Disruptive Technology Achievement Commercialization Fund) |
| Amount Raised | ≈ ¥30 million (≈ US$4.2 million) – “tens of millions of RMB” |
| Use of Proceeds | • Advance lead iPSC‑derived CEC therapy pipeline • Expand early‑stage pipeline (retinal, corneal, other ocular indications) • Scale AI + Compound Reprogramming platform |
| Closing Date | 15 Nov 2025 |
Company & Technology Snapshot
- Founded: September 2024
- Focus: Cell‑therapy drugs for high‑unmet‑need ophthalmic diseases (cornea, retina).
- Core Platforms:
- iPSC Differentiation Platform – proprietary protocols to generate functional corneal endothelial cells from induced pluripotent stem cells.
- AI‑Powered Compound Reprogramming – machine‑learning models accelerate discovery of small‑molecule enhancers that improve cell‑therapy potency and safety.
Lead Product Candidate – iPSC‑Derived Corneal Endothelial Cell Therapy
| Development Milestone | Status |
|---|---|
| Pre‑clinical efficacy | Demonstrated restoration of corneal transparency in rabbit models (≥ 85 % success). |
| IND‑enabling studies | Completed GLP toxicology; filing with NMPA planned Q2 2026. |
| Target Indication | Fuchs endothelial corneal dystrophy & post‑surgical endothelial loss. |
| Differentiation Yield | > 92 % CD‑31⁻/CD‑34⁻/ZO‑1⁺ cells, surpassing industry benchmarks. |
Market Opportunity & Outlook
- China Ophthalmic Cell‑Therapy Market: Projected to exceed ¥12 billion by 2030, driven by an aging population and rising prevalence of corneal endothelial disorders.
- Revenue Forecast (Resight’s Lead Candidate): Assuming 5 % market capture of ≈ 1.2 million annual cases, potential ¥800 million (≈ US$110 million) in sales by 2029.
- Strategic Positioning: Dual‑platform approach (iPSC + AI) offers faster development cycles and the ability to address multiple ocular targets, differentiating Resight from traditional biologics and gene‑therapy competitors.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding financing, product development timelines, and market potential for Resight Therapeutics. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and competitive dynamics.-Fineline Info & Tech